Eisai and MBC BioLabs Announce Winner of Golden Ticket Competition

Eisai and MBC BioLabs announced Deciduous Therapeutics as the winners of their 2021 Golden Ticket Competition. This was the Eisai inaugural competition and the award supports entrepreneurial scientists and emerging biotechnology start-ups to accelerate early drug discovery and innovation for the potential future benefit of patients worldwide.

Entries were received across a broad range of disease areas and exciting innovative technologies from which the winning company was identified. Deciduous Therapeutics was chosen for the potential of their innovation to deliver therapeutic advances for unmet medical needs and their potential synergy with Eisai’ Focus Area Approach. The winner gain one-year usage of MBC BioLabs’ state-of-the-art laboratory facility as well as access to Eisai’s research and development capabilities and business mentors.

About Eisai Innovation

Eisai is a leading global research and development-based pharmaceutical company headquartered in Japan, with
approximately 10,000 employees worldwide. We define our corporate mission as “giving first thought to patients and their
families and to increasing the benefits health care provides,” which we call our human health care (hhc) philosophy. We strive to
realize our hhc philosophy by delivering innovative products in therapeutic areas with high unmet medical needs, including
Oncology and Neurology. In the spirit of hhc, we take that commitment even further by applying our scientific expertise, clinical
capabilities and patient insights to discover and develop innovative solutions that help address society’s toughest unmet needs,
including neglected tropical diseases and the Sustainable Development Goals.

For more information about Eisai, please visit www.eisai.com (for global), us.eisai.com (for U.S.) or www.eisai.eu (for Europe, Middle
East, Africa), and connect with us on Twitter (U.S. and global) and LinkedIn (for U.S.).

About MBC BioLabs

MBC BioLabs is dedicated to helping life-science startups succeed. By renting space as small as a single bench and providing these entrepreneurial scientists with access to millions of dollars of equipment, we allow companies to be fast, focused, and frugal. We now have three sites: one in the Dogpatch neighborhood in San Francisco and two new campuses in San Carlos. Each site has a complete molecular biology core facility that allows companies to do experiments on day one, not year one. We have partnerships with leading pharmaceutical and life-science companies as well as a built-in venture capital firm, Mission Bay Capital. These partnerships provide our entrepreneurs with valuable insights about where to focus their efforts and accelerates the innovation pipeline. Our labs have truly enabled awesome: since our opening in 2013 we have helped launch and grow 230 companies. These companies have brought dozens programs to the clinic, produced multiple approved diagnostics, and raised over $7 billion!